Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers.

Szczegóły
Abstrakt

Tytuł:: Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers.
Autorzy:: Mustachio LM; Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Roszik J; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Farria A; Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Dent SYR; Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas. .; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Źródło:: Cancer research [Cancer Res] 2020 May 15; Vol. 80 (10), pp. 1905-1911. Date of Electronic Publication: 2020 Feb 24.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Publication: Baltimore, Md. : American Association for Cancer Research
Original Publication: Chicago [etc.]
MeSH Terms:: Embryonic Development*
Neoplasms*
Proto-Oncogene Proteins c-myc*
Transcription Factors*
Animals ; Humans ; p300-CBP Transcription Factors
References:: Genes Dev. 2019 Aug 1;33(15-16):888-902. (PMID: 31123066)
Clin Epigenetics. 2016 May 26;8:59. (PMID: 27231488)
Mol Cell. 2017 Oct 5;68(1):130-143.e5. (PMID: 28918903)
Cell Rep. 2016 Oct 18;17(4):1193-1205. (PMID: 27760321)
Cell Res. 2016 May;26(5):629-32. (PMID: 27103431)
EMBO Rep. 2003 Jun;4(6):575-80. (PMID: 12776177)
Plant Mol Biol. 2002 Dec;50(6):925-47. (PMID: 12516863)
Epigenomics. 2014 Jun;6(3):329-39. (PMID: 25111486)
Oncotarget. 2017 Jan 3;8(1):3-14. (PMID: 27980214)
Structure. 2014 Nov 4;22(11):1553-9. (PMID: 25441028)
Expert Rev Anticancer Ther. 2010 Jun;10(6):935-54. (PMID: 20553216)
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11303-6. (PMID: 11027331)
J Biol Chem. 2003 May 30;278(22):20405-12. (PMID: 12660246)
Genome Res. 2018 Feb 14;:. (PMID: 29444801)
PLoS One. 2012;7(6):e39456. (PMID: 22745758)
Oncogenesis. 2015 Feb 09;4:e137. (PMID: 25664930)
Cell. 1996 Mar 22;84(6):843-51. (PMID: 8601308)
Nature. 1996 Jul 25;382(6589):319-24. (PMID: 8684459)
Genes Dev. 1997 Jul 1;11(13):1640-50. (PMID: 9224714)
Med Sci Monit. 2018 Mar 25;24:1742-1750. (PMID: 29574466)
Cancer Discov. 2018 Jan;8(1):24-36. (PMID: 29263030)
Int J Mol Sci. 2017 Jul 05;18(7):. (PMID: 28678170)
J Biol Chem. 2013 May 17;288(20):14510-21. (PMID: 23543735)
Mol Cell. 2009 Aug 14;35(3):352-64. (PMID: 19683498)
Cell Res. 2016 Apr;26(4):484-98. (PMID: 27002218)
J Cell Physiol. 2017 Dec;232(12):3664-3676. (PMID: 28160502)
EMBO Rep. 2011 Sep 01;12(9):924-30. (PMID: 21779003)
Oncol Lett. 2018 Sep;16(3):3955-3963. (PMID: 30128014)
Nat Commun. 2017 Oct 20;8(1):1088. (PMID: 29057918)
Cell Death Dis. 2016 Oct 6;7(10):e2400. (PMID: 27711074)
J Biol Chem. 2017 Feb 17;292(7):2815-2829. (PMID: 28053092)
Int J Mol Sci. 2016 Nov 07;17(11):. (PMID: 27827996)
Mol Cell. 2008 Jan 18;29(1):102-11. (PMID: 18206973)
Trends Mol Med. 2014 Aug;20(8):416-8. (PMID: 24906555)
Cancer Res. 2014 Jan 1;74(1):272-86. (PMID: 24197134)
Angew Chem Int Ed Engl. 2017 Jan 16;56(3):827-831. (PMID: 27966810)
EBioMedicine. 2018 Oct;36:553-562. (PMID: 30224312)
Blood. 2018 Jul 26;132(4):423-434. (PMID: 29844011)
Onco Targets Ther. 2018 May 23;11:3035-3046. (PMID: 29872315)
Front Genet. 2016 Jul 28;7:133. (PMID: 27516771)
J Biol Chem. 2019 Apr 19;294(16):6227-6239. (PMID: 30804216)
Mol Cell Biol. 2009 Mar;29(5):1176-88. (PMID: 19103755)
Cell Commun Signal. 2019 Dec 16;17(1):167. (PMID: 31842906)
Genes Dev. 2012 Mar 15;26(6):527-41. (PMID: 22426530)
Mol Cell. 2012 May 25;46(4):484-94. (PMID: 22542455)
Oncotarget. 2016 Mar 8;7(10):11332-48. (PMID: 26870991)
J Cell Sci. 2019 Jan 16;132(2):. (PMID: 30559249)
Mol Cell. 2011 Nov 4;44(3):410-423. (PMID: 22055187)
Genes Dev. 2015 Apr 15;29(8):803-16. (PMID: 25877919)
Am J Cancer Res. 2019 Aug 01;9(8):1830-1845. (PMID: 31497362)
Nature. 2000 Jun 8;405(6787):701-4. (PMID: 10864329)
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):815-21. (PMID: 22417805)
Epigenetics Chromatin. 2018 Mar 29;11(1):13. (PMID: 29598828)
Biochim Biophys Acta. 2014 May;1839(5):395-405. (PMID: 24705139)
Cell Cycle. 2006 Jun;5(11):1208-16. (PMID: 16760651)
Oncogene. 2012 Feb 2;31(5):643-52. (PMID: 21725360)
Oncogene. 2007 Aug 13;26(37):5329-40. (PMID: 17694076)
Saudi Pharm J. 2017 May;25(4):638-643. (PMID: 28579904)
Stem Cell Reports. 2018 Jan 9;10(1):287-299. (PMID: 29249668)
Nat Genet. 2018 Sep;50(9):1240-1246. (PMID: 30127528)
Cell. 1998 Aug 7;94(3):363-74. (PMID: 9708738)
EMBO J. 2006 Jun 21;25(12):2723-34. (PMID: 16724113)
ACS Chem Biol. 2018 Oct 19;13(10):2862-2867. (PMID: 30200762)
Mol Cell. 2016 May 19;62(4):558-71. (PMID: 27132940)
Oncotarget. 2016 Jul 12;7(28):44848-44856. (PMID: 27057639)
J Med Chem. 2017 Jan 26;60(2):695-709. (PMID: 28002667)
Nucleic Acids Res. 2019 Apr 23;47(7):3383-3394. (PMID: 30715476)
Nat Genet. 2017 Dec;49(12):1779-1784. (PMID: 29083409)
Mol Cell Biol. 2004 Dec;24(24):10826-34. (PMID: 15572685)
Oncotarget. 2019 Oct 08;10(56):5847-5858. (PMID: 31645904)
Nat Genet. 2000 Oct;26(2):229-32. (PMID: 11017084)
Mol Cell. 2008 Jan 18;29(1):92-101. (PMID: 18206972)
EMBO J. 2014 Nov 3;33(21):2534-46. (PMID: 25216679)
Mol Cell. 2004 Feb 27;13(4):573-85. (PMID: 14992726)
Mol Cell Biol. 1999 Jan;19(1):86-98. (PMID: 9858534)
Angew Chem Int Ed Engl. 2018 Dec 10;57(50):16302-16307. (PMID: 30288907)
Cancer Res. 2013 Oct 15;73(20):6323-33. (PMID: 23943798)
Int J Mol Sci. 2015 Sep 10;16(9):21897-910. (PMID: 26378521)
Nat Chem Biol. 2018 Dec;14(12):1140-1149. (PMID: 30374167)
Oncotarget. 2016 Apr 19;7(16):22623-31. (PMID: 26980707)
Cell Biosci. 2016 Aug 02;6:47. (PMID: 27486509)
Development. 2019 Feb 22;146(4):. (PMID: 30718289)
Mol Cell. 2019 Jun 20;74(6):1148-1163.e7. (PMID: 31005419)
Mol Cell Biol. 2000 Jan;20(2):556-62. (PMID: 10611234)
Biol Open. 2019 Feb 18;8(2):. (PMID: 30777878)
Mol Cell Biol. 2013 Apr;33(8):1487-502. (PMID: 23382074)
Cell Rep. 2016 May 17;15(7):1554-1565. (PMID: 27160905)
J Biol Chem. 2015 Nov 27;290(48):28997-9009. (PMID: 26468280)
Epigenetics Chromatin. 2018 Jun 8;11(1):30. (PMID: 29884215)
Ann Oncol. 2017 Aug 1;28(8):1776-1787. (PMID: 28838216)
Am J Cancer Res. 2016 Dec 01;6(12):2772-2786. (PMID: 28042499)
Grant Information:: R01 GM067718 United States GM NIGMS NIH HHS; R01 HD094400 United States HD NICHD NIH HHS; R35 GM131678 United States GM NIGMS NIH HHS
Substance Nomenclature:: 0 (Proto-Oncogene Proteins c-myc)
0 (Transcription Factors)
EC 2.3.1.48 (p300-CBP Transcription Factors)
EC 2.3.1.48 (p300-CBP-associated factor)
Entry Date(s):: Date Created: 20200226 Date Completed: 20201026 Latest Revision: 20201115
Update Code:: 20240105
PubMed Central ID:: PMC7231639
DOI:: 10.1158/0008-5472.CAN-19-3652
PMID:: 32094302
: Czasopismo naukowe

Targeting epigenetic regulators, such as histone-modifying enzymes, provides novel strategies for cancer therapy. The GCN5 lysine acetyltransferase (KAT) functions together with MYC both during normal development and in oncogenesis. As transcription factors, MYC family members are difficult to target with small-molecule inhibitors, but the acetyltransferase domain and the bromodomain in GCN5 might provide alternative targets for disruption of MYC-driven functions. GCN5 is part of two distinct multiprotein histone-modifying complexes, SAGA and ATAC. This review summarizes key findings on the roles of SAGA and ATAC in embryo development and in cancer to better understand the functional relationships of these complexes with MYC family members, as well as their future potential as therapeutic targets.
(©2020 American Association for Cancer Research.)

Informacja